Entwicklung der targetspezifischen Komponente eines Tumor-Pretargeting Systems auf der Basis L-konfigurierter Oligonukleotide

Entwicklung der targetspezifischen Komponente eines Tumor-Pretargeting Systems auf der Basis L-konfigurierter Oligonukleotide

Zur Behandlung von Tumorerkrankungen sind radioaktiv markierte Antikörper als hochaffine und selektive Radioimmuntherapeutika von zunehmender Bedeutung. Allerdings ist der Einsatz solcher radioaktiv markierter Antikörper bei der Behandlung strahlenresistenter solider Tumore limitiert, weil infolge i...

Full description

Bibliographic Details
Main Author:	Schubert, Maik
Other Authors:	Technische Universität Dresden, Fakultät Mathematik und Naturwissenschaften
Format:	Doctoral Thesis
Language:	deu
Published:	Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden 2016
Subjects:	Tumor Pretargeting L-Oligonukleotid Cetuximab PET Radioimmuntherapie Plattenepithelkarzinom Tumor pretargeting L-oligonucleotide cetuximab PET imaging radioimmunotherapy squamous cell carcinoma ddc:540 rvk:VK 8577
Online Access:	http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-193974 http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-193974 http://www.qucosa.de/fileadmin/data/qucosa/documents/19397/2015-Schubert_Entwicklung_der_targetspezifischen_Komponente_eines_Tumor-Pretargeting_Systems.pdf

Similar Items

A pretargeting system for tumor PET imaging and radioimmunotherapy
by: Françoise eKraeber-Bodéré, et al.
Published: (2015-03-01)

Pretargeting for imaging and therapy in oncological nuclear medicine
by: Clément Bailly, et al.
Published: (2017-06-01)

Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry
by: Otto C. Boerman
Published: (2014-11-01)

Improvement of radioimmunotherapy using pretargeting
by: Eric eFrampas, et al.
Published: (2013-06-01)

Evaluation of [<sup>64</sup>Cu]Cu-NOTA-PEG<sub>7</sub>-H-Tz for Pretargeted Imaging in LS174T Xenografts—Comparison to [<sup>111</sup>In]In-DOTA-PEG<sub>11</sub>-BisPy-Tz
by: Christian B. M. Poulie, et al.
Published: (2021-01-01)

Improvement of the Targeting of Radiolabeled and Functionalized Liposomes with a Two-Step System Using a Bispecific Monoclonal Antibody (Anti-CEA × Anti-DTPA–In)
by: Aurore eRauscher, et al.
Published: (2015-11-01)

Pretargeted Imaging with Gallium-68—Improving the Binding Capability by Increasing the Number of Tetrazine Motifs
by: Dominik Summer, et al.
Published: (2018-10-01)

Two Novel PET Radiopharmaceuticals for Endothelial Vascular Cell Adhesion Molecule-1 (VCAM-1) Targeting
by: Sara Pastorino, et al.
Published: (2021-07-01)

A Revisit to the Pretargeting Concept—A Target Conversion
by: Guozheng Liu
Published: (2018-12-01)

Clinical Results in Medullary Thyroid Carcinoma Suggest High Potential of Pretargeted Immuno-PET for Tumor Imaging and Theranostic Approaches
by: Caroline Bodet-Milin, et al.
Published: (2019-06-01)

Therapeutic Applications of Pretargeting
by: Marjolein Verhoeven, et al.
Published: (2019-09-01)

Chapter Pretargeted Theranostics
by: Markus, Staudt
Published: (2021)

A pretargeting nanoplatform for imaging and enhancing anti-inflammatory drug delivery
by: Min Kyung Khang, et al.
Published: (2020-12-01)

A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer
by: Fortuné M. K. Elekonawo, et al.
Published: (2019-09-01)

Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine
by: Sudath Hapuarachchige, et al.
Published: (2020-07-01)

Comparative Evaluation of Novel <sup>177</sup>Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting
by: Hanna Tano, et al.
Published: (2021-01-01)

Evaluation of the inverse electron demand Diels-Alder reaction in rats using a scandium-44-labelled tetrazine for pretargeted PET imaging
by: Patricia E. Edem, et al.
Published: (2019-05-01)

Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update
by: Jonatan Dewulf, et al.
Published: (2020-07-01)

Manipulating the In Vivo Behaviour of <sup>68</sup>Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance
by: Cinzia Imberti, et al.
Published: (2020-02-01)

Wiederholte Anti-CEA-Radioimmuntherapie mit 131I-Labetuzumab nach Resektion kolorektaler Lebermetastasen - Ergebnisse einer monozentrischen Phase I/II-Studie
by: Niessner, Martin Walter
Published: (2018)

PNA-mediated Affibody pretargeting
by: Tano, Hanna
Published: (2017)

Analyse von Bürstenbiopsien oraler Läsionen hinsichtlich der Expression von melanom-assoziierten Antigenen A und Hypoxie-induziertem-Faktor 1 sowie deren Bedeutung in der Diagnostik
by: Kanofsky [geb. Kipke], Romy Ursula Nina
Published: (2020)

Pretargeting of internalizing trastuzumab and cetuximab with a 18F-tetrazine tracer in xenograft models
by: Outi Keinänen, et al.
Published: (2017-12-01)

Differentiation between temporary and real non-clearability of biotinylated IgG antibody by avidin in mice
by: Shuping eDou, et al.
Published: (2014-07-01)

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen
by: Hao Hong, et al.
Published: (2008-01-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

FDG-PET/CT im Vergleich zur MRT im Rahmen des Tumorstagings von Plattenepithelkarzinomen in der Mundhöhle und FDG-PET/CT im Vergleich zur Endoskopie zum Ausschluss von Zweitkarzinomen im oberen Aerodigestivtrakt im Rahmen des Tumorstagings - Eine klinische, retrospektive Studie -
by: Iring, Tobias Maximilian
Published: (2020)

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies
by: Raymond P. Perez, et al.
Published: (2019-12-01)

Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx
by: Mindaugas Grybauskas, et al.
Published: (2014-01-01)

Einflussgrößen der Nephrotoxizität eines Radiotracers am Beispiel der Radioimmuntherapie mit 188Re-anti-CD66
by: Oehme, Liane
Published: (2009)

IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications
by: Maryana Handula, et al.
Published: (2021-07-01)

Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies
by: Françoso A, et al.
Published: (2017-01-01)

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection
by: Cheng, C.-L, et al.
Published: (2022)

PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models
by: Tae Sup Lee, et al.
Published: (2018-10-01)

Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer
by: Aiko Yamaguchi, et al.
Published: (2019-10-01)

A phase II study for metabolic <it>in vivo </it>response monitoring with sequential <sup>18</sup>FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial
by: Berger Anne, et al.
Published: (2012-03-01)

Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
by: Ankur Bahl, et al.
Published: (2020-06-01)

Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
by: Li B, et al.
Published: (2018-11-01)

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study)
by: Yujiro Nishizawa, et al.
Published: (2021-08-01)

Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers
by: Vivek Radhakrishnan, et al.
Published: (2015-11-01)

Cannot write session to /tmp/vufind_sessions/sess_qc0ru1hrp5v3bm8shqo8efgngp